MX2023008251A - Mutantes de fimh, composiciones con estos y uso de estos. - Google Patents

Mutantes de fimh, composiciones con estos y uso de estos.

Info

Publication number
MX2023008251A
MX2023008251A MX2023008251A MX2023008251A MX2023008251A MX 2023008251 A MX2023008251 A MX 2023008251A MX 2023008251 A MX2023008251 A MX 2023008251A MX 2023008251 A MX2023008251 A MX 2023008251A MX 2023008251 A MX2023008251 A MX 2023008251A
Authority
MX
Mexico
Prior art keywords
fimh
mutants
compositions therewith
polypeptides
lectin domain
Prior art date
Application number
MX2023008251A
Other languages
English (en)
Inventor
Jeroen Geurtsen
Eveline Marleen Weerdenburg
Kellen Cristhina Fae
Jan Grijpstra
Louris Jakob Feitsma
Original Assignee
Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc filed Critical Janssen Pharmaceuticals Inc
Publication of MX2023008251A publication Critical patent/MX2023008251A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se describen polipéptidos que comprenden un dominio de lectina FimH que comprenden al menos una mutación de aminoácidos que hace que el dominio de lectina FimH esté en la conformación de baja afinidad por manosa. Se describen adicionalmente composiciones farmacéuticas que comprenden tales polipéptidos y métodos para estimular una respuesta inmunitaria en un sujeto que lo necesita mediante la administración del polipéptido.
MX2023008251A 2021-01-12 2022-01-11 Mutantes de fimh, composiciones con estos y uso de estos. MX2023008251A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21151126 2021-01-12
PCT/IB2022/050166 WO2022153166A1 (en) 2021-01-12 2022-01-11 Fimh mutants, compositions therewith and use thereof

Publications (1)

Publication Number Publication Date
MX2023008251A true MX2023008251A (es) 2023-07-26

Family

ID=74175646

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023008251A MX2023008251A (es) 2021-01-12 2022-01-11 Mutantes de fimh, composiciones con estos y uso de estos.

Country Status (12)

Country Link
US (2) US11725028B2 (es)
EP (1) EP4277921A1 (es)
JP (1) JP2024502854A (es)
KR (1) KR20230125842A (es)
CN (1) CN116888140A (es)
AR (1) AR124604A1 (es)
AU (1) AU2022207740B2 (es)
CA (1) CA3207841A1 (es)
IL (1) IL303954A (es)
MX (1) MX2023008251A (es)
TW (1) TW202241929A (es)
WO (1) WO2022153166A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023111907A1 (en) * 2021-12-17 2023-06-22 Pfizer Inc. Polynucleotide compositions and uses thereof

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4987237A (en) 1983-08-26 1991-01-22 Ribi Immunochem Research, Inc. Derivatives of monophosphoryl lipid A
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
JPH0655749B2 (ja) 1989-09-20 1994-07-27 日本たばこ産業株式会社 リピッドａ単糖類縁体
US5370872A (en) 1991-08-12 1994-12-06 Swiss Serum And Vaccine Institute Berne Escherichia coliO-polysaccharide-protein conjugate vaccine
US5593969A (en) 1991-09-03 1997-01-14 Igen Incorporated Lipid-A analogs: monosaccharide and dissaccharide compounds for inhibiting binding of lipid A receptors to lipid A receptors
JP3755890B2 (ja) 1992-06-25 2006-03-15 スミスクライン・ビーチャム・バイオロジカルス（ソシエテ・アノニム） アジュバント含有ワクチン組成物
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
ES2227825T3 (es) 1997-04-01 2005-04-01 Corixa Corporation Composiciones inmunologicas aduvantes acuosas de monofosforil lipido a.
US6491919B2 (en) 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
US6500434B1 (en) 1998-04-23 2002-12-31 Medimmune, Inc. Chaperone and adhesin proteins; vaccines, diagnostics and method for treating infections
US6858211B1 (en) 1998-07-20 2005-02-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccines against Escherichia coli O157 infection
TR200101055T2 (tr) 1998-10-16 2001-09-21 Smithkline Beecham Biologicals S.A. Adjuvan sistemler ve aşılar
EP1194563A1 (en) * 1999-07-15 2002-04-10 Medimmune, Inc. Fimh adhesin-based vaccines
WO2001025254A2 (en) 1999-10-04 2001-04-12 University Of Maryland Biotechnology Institute Novel adjuvant comprising a lipopolysaccharide antagonist
WO2001078777A2 (en) 2000-04-13 2001-10-25 Mossman, Sally Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and qs-21
WO2002004496A2 (en) 2000-07-07 2002-01-17 Medimmune, Inc. Fimh adhesin proteins and methods of use
EP1313502A4 (en) 2000-08-18 2005-10-19 Medimmune Inc ADMINISTRATIVE PROCEDURE OF FIMH PROTEIN AS A VACCINE AGAINST HARNWAY INFECTIONS
AU2001297896A1 (en) * 2000-12-08 2003-01-02 Medimmune, Inc. Mutant proteins, high potency inhibitory antibodies and fimch crystal structure
US6676958B2 (en) 2001-06-19 2004-01-13 Advanced Bioadjuvants, Llc Adjuvant composition for mucosal and injection delivered vaccines
CN101019123A (zh) * 2004-02-06 2007-08-15 科学与工业研究委员会 用于识别有治疗潜力的粘附素和粘附素样蛋白的计算方法
AU2006241206B2 (en) 2005-04-26 2011-06-09 Eisai R&D Management Co., Ltd. Compositions and methods for cancer immunotherapy
CN101360831B (zh) 2005-05-11 2013-07-10 Eth苏黎世公司 来自原核细胞的重组n-糖基化蛋白
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
WO2007109812A2 (en) 2006-03-23 2007-09-27 Novartis Ag Immunopotentiating compounds
EP2010537B1 (en) 2006-03-23 2011-12-28 Novartis AG Imidazoquinoxaline compounds as immunomodulators
JP5782258B2 (ja) 2008-02-20 2015-09-24 グリコヴァキシン アーゲー 原核細胞由来の組換えｎ−グリコシル化タンパク質から作製したバイオコンジュゲート
RU2560182C2 (ru) 2009-06-05 2015-08-20 Инфекшес Дизиз Рисерч Инститьют Синтетические глюкопиранозиллипидные адъюванты
TR201908003T4 (tr) 2012-02-07 2019-06-21 Infectious Disease Res Inst TLR4 agonistleri içeren gelişmiş adjuvan formülasyonları ve bunların kullanım metotları.
MX354057B (es) 2013-05-18 2018-02-09 The Regents Of The Univ Of California Star Composiciones y métodos para activar la señalización dependiente del "estimulador del gene de interferón".
US9504743B2 (en) 2013-09-25 2016-11-29 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9415101B2 (en) 2013-09-25 2016-08-16 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9017698B2 (en) 2013-09-25 2015-04-28 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149522B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9415097B2 (en) 2013-09-25 2016-08-16 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149521B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
SG11201606889PA (en) 2014-02-24 2016-09-29 Glycovaxyn Ag Novel polysaccharide and uses thereof
JP2018515517A (ja) * 2015-05-13 2018-06-14 ユニバーシティ オブ ワシントンＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｗａｓｈｉｎｇｔｏｎ 尿路病原性大腸菌感染病の処置と予防のための組成物および方法
IL288541B (en) 2015-07-07 2022-08-01 Janssen Vaccines Prevention B V vaccine against rsv
TWI715617B (zh) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
US11723985B2 (en) * 2017-09-08 2023-08-15 Cytoseek Limited Protein delivery to membranes
WO2019175147A1 (en) 2018-03-12 2019-09-19 Janssen Vaccines & Prevention B.V. Vaccines against intra-abdominal infections
EP4077372A1 (en) * 2019-12-20 2022-10-26 Vib Vzw Nanobody exchange chromatography
JP7485771B2 (ja) * 2020-01-16 2024-05-16 ヤンセン ファーマシューティカルズ，インコーポレーテッド ＦｉｍＨ変異体、その組成物、及びその使用

Also Published As

Publication number Publication date
AU2022207740A1 (en) 2023-06-29
WO2022153166A1 (en) 2022-07-21
KR20230125842A (ko) 2023-08-29
US20220220159A1 (en) 2022-07-14
US11725028B2 (en) 2023-08-15
JP2024502854A (ja) 2024-01-23
TW202241929A (zh) 2022-11-01
AU2022207740B2 (en) 2024-06-06
EP4277921A1 (en) 2023-11-22
IL303954A (en) 2023-08-01
US20230406890A1 (en) 2023-12-21
CN116888140A (zh) 2023-10-13
AR124604A1 (es) 2023-04-12
CA3207841A1 (en) 2022-07-21

Similar Documents

Publication Publication Date Title
MX2022008830A (es) Mutante de fimh, composiciones que lo contienen y uso de éste.
NZ761434A (en) Cytokine conjugates for the treatment of autoimmune diseases
MX2021005092A (es) Andamiajes de la subunidad a de la toxina shiga desinmunizados y moleculas con direccion a las celulas que los comprenden.
MX2018001567A (es) Novedosos polipeptidos de fusion especificos para lag-3 y pd-1.
de Melo et al. Immunomodulatory response of Cramoll 1, 4 lectin on experimental lymphocytes
MX2021002764A (es) Composiciones para el tratamiento de enfermedades con conjugados inmunoestimuladores.
MX2021006017A (es) Polipeptidos de folistatina y sus usos.
De Melo et al. Mitogenic response and cytokine production induced by cramoll 1, 4 lectin in splenocytes of inoculated mice
MX2020001525A (es) Composiciones de peptido similar al glucagon tipo 1 (glp-1) y sus usos.
HRP20231437T1 (hr) Il-15 i il-15ralpha sushi domena na temelju modulokina
BR112018001572A2 (pt) método para induzir uma resposta imune, antígeno, adenovírus, uso de um antígeno e de um adenovírus, e, polinucleotídeo.
NZ770137A (en) Lactobacillus gasseri kbl697 strain and use thereof
MX2021005365A (es) Preparaciones y composiciones de oligosacaridos.
MA45172B1 (fr) Arn modifié codant pour des polypeptides vegf-a, formulations et utilisations associées
MX2023008251A (es) Mutantes de fimh, composiciones con estos y uso de estos.
MX2019007144A (es) Nuevos agonistas de tnfr y sus usos.
MX2017015037A (es) Composiciones nutritivas que contienen un nivel elevado de inositol y usos de las mismas.
PH12019502617A1 (en) Antibody-cytokine engrafted proteins and methods of use for immune related disorders
PH12021550705A1 (en) Stable semaglutide compositions and uses thereof
MX2021003109A (es) Proteina para el tratamiento de enfermedades inflamatorias.
MX2019009952A (es) Formulaciones de evolocumab de baja viscosidad y alta concentracion y metodos de elaboracion de las mismas.
Behera et al. Biochemical analysis and antitumour effect of Abrus precatorius agglutinin derived peptides in Ehrlich's ascites and B16 melanoma mice tumour model
CR20210499A (es) Compuestos y composiciones como moduladores de la señalización de tlr
BR112021021839A2 (pt) Composições imunomodulatórias e métodos
MX2023008191A (es) Productos bioterapéuticos hipoinmunogénicos.